Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients - Trial NCT06397781
Access comprehensive clinical trial information for NCT06397781 through Pure Global AI's free database. This Phase 4 trial is sponsored by Boston Children's Hospital and is currently Not yet recruiting. The study focuses on Atopic Dermatitis. Target enrollment is 50 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Boston Children's Hospital
Timeline & Enrollment
Phase 4
May 01, 2024
Jul 01, 2028
Primary Outcome
Severity Scoring of Atopic Dermatitis Index
Summary
Our hypothesis is that S. aureus skin decolonization in atopic dermatitis reduces disease
 severity and favorably alters the function and gene expression of epidermal and immune skin
 cells that contribute to disease severity.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06397781
Non-Device Trial